Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TAK-280 by Takeda Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
TAK-280 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Data Insights
TAK-280 by Takeda Pharmaceutical for Small-Cell Lung Cancer: Likelihood of Approval
TAK-280 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...